keyword
MENU ▼
Read by QxMD icon Read
search

Daclatasvir

keyword
https://www.readbyqxmd.com/read/29225269/late-relapse-after-a-sustained-virologic-response-at-24-weeks-after-treatment-with-daclatasvir-and-asunaprevir-combination-therapy-for-chronic-hepatitis-c-virus-genotype-1b-infection-with-liver-cirrhosis
#1
Haruki Uojima, Shuko Murakami, Seigo Nakatani, Hisashi Hidaka, Atsuko Takeuchi, Yoshiaki Tanaka, Tomoyoshi Inoue, Keiko Yamane, Kousuke Kubota, Takahide Nakazawa, Akitaka Shibuya, Yasuhito Tanaka, Wasaburo Koizumi
There have been few studies on relapse after a sustained virological response in hepatitis C virus (HCV) patients treated with interferon-free regimens. Thus, the risk of late relapse in patients treated with interferon-free therapy remains unclear. A 67-year-old woman with HCV genotype 1b and liver cirrhosis received oral daclatasvir and asunaprevir. Combination therapy was stopped after 4 weeks because of an episode of encephalopathy. Nonetheless, an HCV polymerase chain reaction at 24 weeks posttreatment was negative...
December 8, 2017: Internal Medicine
https://www.readbyqxmd.com/read/29217095/sofosbuvir-plus-daclatasvir-as-an-alternative-for-patients-on-haemodialysis-with-genotype-2-hepatitis-c-virus-infection
#2
Jara Llenas-García, Sergio Padilla, Mar Masiá, Félix Gutiérrez
No abstract text is available yet for this article.
December 4, 2017: Enfermedades Infecciosas y Microbiología Clínica
https://www.readbyqxmd.com/read/29216198/hcv-kinetic-and-modeling-analyses-project-shorter-durations-to-cure-under-combined-therapy-with-daclatasvir-and-asunaprevir-in-chronic-hcv-infected-patients
#3
Laetitia Canini, Michio Imamura, Yoshiiku Kawakami, Susan L Uprichard, Scott J Cotler, Harel Dahari, Kazuaki Chayama
BACKGROUND & AIMS: High cure rates are achieved in HCV genotype-1b patients treated with daclatasvir and asunaprevir, DCV/ASV. Here we analyzed early HCV kinetics in genotype-1b infected Japanese subjects treated with DCV/ASV and retrospectively projected, using mathematical modeling, whether shorter treatment durations might be effective. METHODS: HCV RNA levels were measured frequently during DCV/ASV therapy in 95 consecutively treated patients at a single center in Japan...
2017: PloS One
https://www.readbyqxmd.com/read/29212314/rapid-changes-in-serum-lipid-profiles-during-combination-therapy-with-daclatasvir-and-asunaprevir-in-patients-infected-with-hepatitis-c-virus-genotype-1b
#4
Takeshi Chida, Kazuhito Kawata, Kazuyoshi Ohta, Erika Matsunaga, Jun Ito, Shin Shimoyama, Satoru Yamazaki, Hidenao Noritake, Tetsuro Suzuki, Takafumi Suda, Yoshimasa Kobayashi
Background/Aims: Changes in lipid profiles in patients infected with hepatitis C virus (HCV) during direct-acting antiviral therapy have been reported in recent years. However, the clinical aspects of disturbed lipid metabolism in chronic HCV infection have not been fully elucidated. Methods: Dynamic changes in serum total, low-density lipoprotein (LDL), and high-density lipoprotein (HDL) cholesterol and apolipoprotein levels in patients infected with HCV genotype 1b were examined during combination therapy with daclatasvir (DCV) and asunaprevir (ASV)...
December 8, 2017: Gut and Liver
https://www.readbyqxmd.com/read/29205432/sofosbuvir-and-daclatasvir-therapy-in-patients-with-hepatitis-c-related-advanced-decompensated-liver-disease-meld-%C3%A2-15
#5
G W McCaughan, P A Thwaites, S K Roberts, S I Strasser, J Mitchell, B Morales, S Mason, P Gow, A Wigg, C Tallis, G Jeffrey, J George, A J Thompson, F C Parker, P W Angus
BACKGROUND: Antiviral therapy for hepatitis C has the potential to improve liver function in patients with decompensated cirrhosis. AIMS: To examine the virological response and effect of viral clearance in patients with decompensated hepatitis C cirrhosis all with MELD scores ≥15 following sofosbuvir/daclatasvir ± ribavirin. METHODS: We prospectively collected data on patients who commenced sofosbuvir/daclatasvir for 24-weeks under the Australian patient supply program (TOSCAR) and analysed outcomes including sustained viral response at 12 weeks (SVR12), death and transplant...
December 5, 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/29197145/long-term-follow-up-of-ribavirin-free-daa-based-treatment-in-hcv-recurrence-after-orthotopic-liver-transplantation
#6
Sandra Beinhardt, Ramona Al-Zoairy, Karin Kozbial, Albert Friedrich Stättermayer, Andreas Maieron, Rudolf Stauber, Michael Strasser, Heinz Zoller, Ivo Graziadei, Susanne Rasoul-Rockenschaub, Michael Trauner, Peter Ferenci, Harald Hofer
BACKGROUND & AIMS: Excellent efficacy and safety-profile of second generation DAA-combinations improved treatment of chronic hepatitis C (HCV) as well as in HCV-recurrence after orthothopic liver transplantation (OLT). The need of ribavirin-addition is under debate as anemia and decreased renal function are prevalent in transplant-cohorts. Aim of this study was thus to assess safety and long-term efficacy of RBV-free DAA-combinations in HCV-recurrent patients after OLT. PATIENTS & METHODS: 62 OLT-recipients (male:50/81%; age:60...
December 2, 2017: Liver International: Official Journal of the International Association for the Study of the Liver
https://www.readbyqxmd.com/read/29194858/low-incidence-of-hepatitis-b-virus-reactivation-and-subsequent-hepatitis-in-patients-with-chronic-hepatitis-c-receiving-direct-acting-antiviral-therapy
#7
Akihiro Tamori, Seigo Abiru, Hirayuki Enomoto, Kiyohide Kioka, Masaaki Korenaga, Joji Tani, Masaru Enomoto, Masaya Sugiyama, Tsutomu Masaki, Norifumi Kawada, Hiroshi Yatsuhashi, Shuhei Nishiguchi, Masashi Mizokami
To determine the clinical characteristics of hepatitis B virus (HBV) reactivation in patients undergoing interferon-free anti-hepatitis C virus (HCV) therapy, we examined HBV DNA in 25 HBV co-infected patients and 765 patients with resolved HBV infection during and after treatment with direct-acting antiviral agents (DAAs). Among those with HCV genotype 1, asunaprevir plus daclatasvir was administered to 160 patients, sofosbuvir (SOF) plus ledipasvir to 438 patients, and paritaprevir plus ombitasvir and ritonavir to 25 patients...
November 30, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/29193356/sofosbuvir-plus-daclatasvir-with-or-without-ribavirin-is-safe-and-effective-for-post-transplant-hepatitis-c-recurrence-and-severe-fibrosis-and-cirrhosis-a-prospective-study
#8
Raffaella Lionetti, Vincenza Calvaruso, Paola Piccolo, Rossella Letizia Mancusi, Chiara Mazzarelli, Stefano Fagiuoli, Marzia Montalbano, Ilaria Lenci, Paola Carrai, Giovanni Guaraldi, Ubaldo Visco-Comandini, Martina Milana, Marco Biolato, Laura Loiacono, Giovanna Valente, Antonio Craxì, Mario Angelico, Gianpiero D'offizi
BACKGROUND: In 2012 an Italian Named Patient Program began for hepatitis C virus (HCV)-infected liver transplant (LT) recipients with advanced fibrosis, before approval of direct antiviral agents (DAA), to benefit severely ill patients. Aim of this "real-life" study was to assess treatment efficacy and safety with an extended course of daclatasvir (DCV) plus sofosbuvir (SOF) with or without ribavirin (RBV). METHODS: All HCV LT recipients with severe fibrosis in 15 Italian transplant centers were treated with DCV+SOF±RBV for 24 weeks; sustained virological response was assessed at 12 weeks post-treatment (SVR12)...
November 29, 2017: Clinical Transplantation
https://www.readbyqxmd.com/read/29193226/generic-daclatasvir-plus-sofosbuvir-with-or-without-ribavirin-in-treatment-of-chronic-hepatitis-c-real-world-results-from-18-378-patients-in-egypt
#9
H Omar, W El Akel, T Elbaz, M El Kassas, K Elsaeed, H El Shazly, M Said, M Yousif, A A Gomaa, A Nasr, M AbdAllah, M Korany, S A Ismail, M K Shaker, W Doss, G Esmat, I Waked, Y El Shazly
BACKGROUND: Treatment of chronic hepatitis C using combination of sofosbuvir (SOF) and daclatasvir (DCV) was used in several clinical trials and multicentre studies, which were somewhat limited to genotypes 1-3. The national program in Egypt is using SOF-DCV combination for large scale treatment. AIM: To assess the efficacy and safety of combined SOF-DCV in treating patients with HCV-G4 in a real-world setting. METHODS: Data and outcome of chronic HCV patients who were treated for 12 weeks with generic medications: DCV 60 mg plus SOF 400 mg ± ribavirin (RBV) within the national hepatitis C treatment program in Egypt are presented...
November 29, 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/29180522/integrated-resistance-analysis-of-certain-1-and-certain-2-studies-in-hcv-infected-patients-receiving-glecaprevir-and-pibrentasvir-in-japan
#10
Preethi Krishnan, Gretja Schnell, Rakesh Tripathi, Jill Beyer, Thomas Reisch, Tatyana Dekhtyar, Michelle Irvin, Wangang Xie, Bo Fu, Margaret Burroughs, Rebecca Redman, Hiromitsu Kumada, Kazuaki Chayama, Christine Collins, Tami Pilot-Matias
Glecaprevir and pibrentasvir are hepatitis C virus (HCV) pangenotypic inhibitors targeting NS3/4A protease and NS5A, respectively. This once-daily, fixed-dose combination regimen demonstrated high SVR12 rates in CERTAIN-1 and CERTAIN-2 studies in Japanese HCV-infected patients, with a low virologic failure (VF) rate (1.2%). There were no VFs among direct acting antiviral (DAA)-treatment-naive genotype (GT)1a- (n=4), GT1b- (n=128), and GT2- (n=97) infected non-cirrhotic patients treated for 8 weeks, or GT1b- (n=38) or GT2- (n=20) infected patients with compensated cirrhosis treated for 12 weeks...
November 27, 2017: Antimicrobial Agents and Chemotherapy
https://www.readbyqxmd.com/read/29146520/patterns-of-resistance-associated-substitutions-in-patients-with-chronic-hcv-infection-following-treatment-with-direct-acting-antivirals
#11
Julia Dietz, Simone Susser, Johannes Vermehren, Kai-Henrik Peiffer, Georgios Grammatikos, Annemarie Berger, Peter Ferenci, Maria Buti, Beat Müllhaupt, Bela Hunyady, Holger Hinrichsen, Stefan Mauss, Jörg Petersen, Peter Buggisch, Gisela Felten, Dietrich Hüppe, Gaby Knecht, Thomas Lutz, Eckart Schott, Christoph Berg, Ulrich Spengler, Thomas von Hahn, Thomas Berg, Stefan Zeuzem, Christoph Sarrazin
BACKGROUND & AIMS: Little is known about substitutions that mediate resistance of HCV to direct-acting antivirals (DAAs), due to the small number of patients with treatment failure in approval studies. It is important to identify resistance patterns to select effective salvage treatments. METHODS: We performed a comprehensive analysis for resistance-associated substitutions (RASs) in HCV genes (NS3, NS5A, NS5B) targeted by DAAs. We compared NS3, NS5A, and NS5B sequences from 626 patients in Europe with DAA failure with sequences from 2322 DAA-naïve patients, infected with HCV genotypes 1-4...
November 13, 2017: Gastroenterology
https://www.readbyqxmd.com/read/29145802/effectiveness-of-current-and-future-regimens-for-treating-genotype-3-hepatitis-c-virus-infection-a-large-scale-systematic-review
#12
Hosnieh Fathi, Andrew Clark, Nathan R Hill, Geoffrey Dusheiko
BACKGROUND: Six distinct genetic variants (genotypes 1 - 6) of hepatitis C virus (HCV) exist globally. Certain genotypes are more prevalent in particular countries or regions than in others but, globally, genotype 3 (GT3) is the second most common. Patients infected with HCV GT1, 2, 4, 5 or 6 recover to a greater extent, as measured by sustained virological response (SVR), following treatment with regimens based on direct-acting antivirals (DAAs) than after treatment with older regimens based on pegylated interferon (Peg-IFN)...
November 16, 2017: BMC Infectious Diseases
https://www.readbyqxmd.com/read/29139181/direct-antiviral-treatment-of-chronic-hepatitis-c-in-heart-transplant-recipients
#13
Martina Vitrone, Roberto Andini, Irene Mattucci, Ciro Maiello, Luigi Atripaldi, Emanuele Durante-Mangoni, Rosa Zampino
Direct-acting antiviral agents (DAAs) are a safe and effective treatment for chronic hepatitis C (CHC). This may be particularly valuable for patients with severe comorbidities or baseline conditions, including non-liver solid organ transplant. We report cases of two heart transplant recipients with CHC treated with DAA (sofosbuvir and daclatasvir) achieving sustained virological response. Treatment was well tolerated and no relevant side effects were observed. The drug-drug interactions and graft function were carefully monitored...
November 15, 2017: Transplant Infectious Disease: An Official Journal of the Transplantation Society
https://www.readbyqxmd.com/read/29137590/a-closing-chapter-hepatitis-c-genotype-3-elimination-in-liver-transplant-sofosbuvir-daclatasvir-in-a-hard-to-treat-population
#14
Eva Maria Teegen, Brigitta Globke, Eckart Schott, Johann Pratschke, Dennis Eurich
OBJECTIVES: Historically, hepatitis C virus genotype 3 infection has not been as hard to treat as genotype 1 using interferon-based therapy. Now, genotype 3 infection can be treated using interferon-free regimes such as the combination of sofosbuvir and daclatasvir, which is a highly successful and reliable therapeutic option before liver transplant. However, real world data are rather limited regarding the use of antivirals (sofosbuvir/daclatasvir) for hepatitis C virus genotype 3 recurrence after liver transplant...
November 15, 2017: Experimental and Clinical Transplantation
https://www.readbyqxmd.com/read/29135824/shortened-8-weeks-course-of-dual-sofosbuvir-daclatasvir-therapy-in-adolescent-patients-with-chronic-hepatitis-c-infection
#15
Mortada El-Shabrawi, Alaa M Abdo, Hisham El-Khayat, Mostafa Yakoot
Recently, sofosbuvir and the fixed dose combination of sofosbuvir/ ledipasvir were approved for the treatment of chronic hepatitis C virus infection (HCV) in adolescents, 12 years old and above or weighing at least 35 kilograms. Here we present the results of a pilot single cohort of 10 consecutive adolescent patients with chronic HCV and treated with dual sofosbuvir/daclatasvir (SOF/DCV) therapy for a response-tailored duration of 8 weeks for those who achieved very rapid virologic response (vRVR) and 12 weeks for those who did not...
November 10, 2017: Journal of Pediatric Gastroenterology and Nutrition
https://www.readbyqxmd.com/read/29125670/use-of-a-hepatitis-c-virus-hcv-rna-positive-donor-in-a-treated-hcv-rna-negative-liver-transplant-recipient
#16
Isabel Campos-Varela, Eliana Z Agudelo, Monika Sarkar, John P Roberts, Norah A Terrault
The shortage of livers has led most transplant centers to use extended criteria donors. Hepatitis C virus (HCV) RNA-positive donors are typically not given to patients who have cleared HCV. A 64-year-old male with chronic hepatitis C, genotype 1b was listed for LT with hepatocellular carcinoma. While on the waiting list, the patient was treated with sofosbuvir, ledipasvir, and ribavirin and achieved an HCV RNA <15 IU/mL by week 10. At week 18 of a planned 24-week treatment course, the patient underwent deceased-donor LT and received an organ from an anti-HCV-positive donor...
November 10, 2017: Transplant Infectious Disease: An Official Journal of the Transplantation Society
https://www.readbyqxmd.com/read/29111616/daclatasvir-and-asunaprevir-treatment-in-patients-infected-by-genotype-1b-of-hepatitis-c-virus-with-no-or-subtle-resistant-associated-substitutions-ras-in-ns5a-y93
#17
Masatoshi Ishigami, Kazuhiko Hayashi, Takashi Honda, Teiji Kuzuya, Yoji Ishizu, Tetsuya Ishikawa, Isao Nakano, Fumihiro Urano, Takashi Kumada, Kentaro Yoshioka, Yoshiki Hirooka, Hidemi Goto
(Backgrounds and Aims) In this study, we investigated the real-world data of the first approved interferon free regimen in Japan; daclatasvir and asunaprevir (DCV+ASV) in chronic hepatitis C patients infected HCV genotype 1b with no or subtle amount of baseline resistant associated substitutions (RAS). (Patients and Methods) Among 924 patients registered in our multicenter study, 750 patients that were proven not to be infected with NS5A-Y93H resistant associated substitutions (RAS) by direct sequencing and to have no or subtle amount (less than 20%) of NS5A-Y93H RAS by probe assays (Cycleave or PCR invader assay) were included in this study...
November 7, 2017: Journal of Medical Virology
https://www.readbyqxmd.com/read/29111569/the-influence-of-immunosuppressants-on-direct-acting-antiviral-therapy-is-dependent-on-hepatitis-c-virus-genotype
#18
Alexandra Frey, Katja Piras-Straub, Andreas Walker, Jörg Timm, Guido Gerken, Kerstin Herzer
BACKGROUND: Direct-acting antivirals (DAA) have substantially increased sustained virological response rates after liver transplantation, with improved tolerance compared to interferon-based therapy. The influence of immunosuppressive agents on the efficacy of DAAs has not been clarified. METHODS: Subgenomic HCV replicons for genotype (GT) 1b, 2b, 3a and 4a were treated with the mammalian target of rapamycin (mTOR) inhibitors everolimus and sirolimus or with the calcineurin inhibitors (CNI) cyclosporine or tacrolimus, either alone or in combination with selected DAAs...
November 7, 2017: Transplant Infectious Disease: An Official Journal of the Transplantation Society
https://www.readbyqxmd.com/read/29094205/association-between-alanine-aminotransferase-elevation-and-ugt1a1-6-polymorphisms-in-daclatasvir-and-asunaprevir-combination-therapy-for-chronic-hepatitis-c
#19
Shinya Maekawa, Mitsuaki Sato, Natsuhiko Kuratomi, Taisuke Inoue, Yuichiro Suzuki, Akihisa Tatsumi, Mika Miura, Shuya Matsuda, Masaru Muraoka, Natsuko Nakakuki, Fumitake Amemiya, Shinichi Takano, Mitsuharu Fukasawa, Yasuhiro Nakayama, Tatsuya Yamaguchi, Tadashi Sato, Minoru Sakamoto, Miyako Murakawa, Mina Nakagawa, Yasuhiro Asahina, Nobuyuki Enomoto
BACKGROUND: Liver damage presented as alanine aminotransferase (ALT) elevation and high ALT-caused treatment discontinuation occurs with high frequency in Japanese patients receiving daclatasvir plus asunaprevir (DCV/ASV) therapy for hepatitis C virus (HCV) infection, and its mechanism is unknown. METHODS: A total of 247 Japanese patients consisting of two independent cohorts with genotype-1b HCV infection receiving DCV/ASV therapy were included. The association of ALT levels during therapy and single nucleotide polymorphisms (SNP) of five drug-metabolizing enzyme loci selected for their possible influence on NS3/4A and NS5A inhibitors was investigated...
November 1, 2017: Journal of Gastroenterology
https://www.readbyqxmd.com/read/29091211/influence-of-abcb11-and-hnf4%C3%AE-genes-on-daclatasvir-plasma-concentration-preliminary-pharmacogenetic-data-from-the-kineti-c-study
#20
Jessica Cusato, Amedeo De Nicolò, Lucio Boglione, Fabio Favata, Alessandra Ariaudo, Simone Mornese Pinna, Federica Guido, Valeria Avataneo, Chiara Carcieri, Giuseppe Cariti, Giovanni Di Perri, Antonio D'Avolio
Background: Daclatasvir is an inhibitor of HCV non-structural 5A protein and is a P-glycoprotein substrate. Pharmacogenetics has had a great impact on previous anti-HCV therapies, particularly considering the association of IL-28B polymorphisms with dual therapy outcome. Objectives: We investigated the association between daclatasvir plasma concentrations at 2 weeks and 1 month of therapy and genetic variants (SNPs) in genes encoding transporters and nuclear factors (ABCB1, ABCB11 and HNF4α)...
October 1, 2017: Journal of Antimicrobial Chemotherapy
keyword
keyword
40093
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"